Imeglimin is under clinical development by Poxel and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imeglimin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imeglimin overview
Imeglimin (Twymeeg) is an antidiabetic agent. It is formulated as film coated tablets for oral route of administration. Twymeeg is indicated for the treatment of type 2 diabetes.
Imeglimin (EMD-387008) is under development for the treatment of type II diabetes. The drug candidate is administered orally in the form of tablet. It is a new chemical entity. Imeglimin is a first in a tetrahydrotriazine-containing class of anti-diabetic drugs, the Glimins. It was also under development for diabetic cardiomyopathy and chronic kidney disease stage 3b/4.
Poxel overview
Poxel is a biopharmaceutical company that primarily focuses on the development of innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and certain rare inherited disorders. The company’s main activities focuses on clinical programs based on its adenosine monophosphate-activated protein kinase (AMPK) activator and modified deuterated thiazolidinedione (TDZ) platforms. Poxel’s major products include PXL065, a drug candidate for the treatment of NASH, and PXL770, a first-in-class direct activator of AMPK being developed for rare diseases. The company also markets TWYMEEG (Imeglimin), a drug approved for the treatment of type 2 diabetes. These products are primarily targeted at patients suffering from metabolic diseases and rare disorders. The company operates in Europe, Japan, the US and France. Poxel is headquartered in Lyon, Auvergne, France.
For a complete picture of Imeglimin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
